Filtered By:
Condition: Bleeding
Management: Insurance

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 143 results found since Jan 2013.

Efficacy and Safety of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study.
This study aimed to compare the efficacy and safety of ticagrelor versus clopidogrel in East Asian patients with AMI. Between July 2013 and December 2015, patients with AMI prescribed with dual antiplatelet therapy were identified from the National Health Insurance Research Database of Taiwan. Using propensity score weighting, ticagrelor was compared with clopidogrel for the primary efficacy endpoint (a composite of all-cause death, MI, and stroke) and bleeding. A total of 32,442 patients with AMI (ticagrelor: 10,057; clopidogrel: 22,385) were eligible for analysis. After propensity score weighting, ticagrelor was comparab...
Source: Clinical Pharmacology and Therapeutics - August 6, 2020 Category: Drugs & Pharmacology Authors: Chang CJ, Tung YC, Liu JR, Chang SH, Kuo CT, See LC Tags: Clin Pharmacol Ther Source Type: research

Increased Incident Ischemic Stroke Risk in Advanced Kidney Disease: A Large-Scale Real-World Data Study
Conclusion: Although we found that OAC use was effective and recommended for patients with AF, advanced kidney disease is still an independent risk factor for IS/SE, even in patients taking OAC. Physicians should be aware of this risk and strictly control modifiable risk factors, regardless of OAC use.Am J Nephrol
Source: American Journal of Nephrology - July 29, 2020 Category: Neurology Source Type: research

Increased Incident Ischemic Stroke Risk in Advanced Kidney Disease: A Large-Scale Real-World Data Study.
CONCLUSION: Although we found that OAC use was effective and recommended for patients with AF, advanced kidney disease is still an independent risk factor for IS/SE, even in patients taking OAC. Physicians should be aware of this risk and strictly control modifiable risk factors, regardless of OAC use. PMID: 32726780 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - July 28, 2020 Category: Urology & Nephrology Authors: Maeda T, Nishi T, Funakoshi S, Tada K, Tsuji M, Satoh A, Kawazoe M, Yoshimura C, Arima H Tags: Am J Nephrol Source Type: research

Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Conclusion: In cancer patients with AF, NOAC were associated with significant reduced IS/SE, major bleeding, and ICH compared to warfarin.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Victor Chien-Chia Wu, Chun-Li Wang, Yu-Tung Huang, Wen-Ching Lan, Michael Wu, Chang-Fu Kuo, Shao-Wei Chen, Pao-Hsien Chu, Ming-Shien Wen, Chi-Ching Kuo, Shang-Hung Chang Tags: Research Paper Source Type: research

Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial.
Abstract IMPACT-AFib was an 80,000-patient randomized clinical trial implemented by five US insurance companies (health plans) aimed at increasing the use of oral anticoagulants by individuals with atrial fibrillation who were at high risk of stroke and not on treatment. The underlying thesis was that patients could be change agents to initiate prescribing discussions with their providers. We tested the effect of mailing information to both patients and their providers. We used administrative medical claims and pharmacy dispensing data to identify eligible patients, to randomize them to an early or delayed interve...
Source: Clinical Trials - June 25, 2020 Category: Research Authors: Garcia CJ, Haynes K, Pokorney SD, Lin ND, McMahill-Walraven C, Nair V, Parlett L, Martin D, Al-Khalidi HR, McCall D, Granger CB, Platt R, Cocoros NM Tags: Clin Trials Source Type: research

Evaluating Effectiveness and Safety in Chronic Kidney Disease with Atrial Flutter Using an Anticoagulation Strategy.
Conclusions: In the studied population, OAC or APT alone were proved equally effective for stroke prophylaxis. Furthermore, OAC might reduce the all-cause mortality rate compared with APT and should be considered as the first choice of oral antithrombotic drugs in patients with AFL and CKD. PMID: 32481685 [PubMed - in process]
Source: Medicina (Kaunas) - May 27, 2020 Category: Universities & Medical Training Authors: Wang YT, Chen CY, Bair MJ Tags: Medicina (Kaunas) Source Type: research

Oral Anticoagulants and Antiplatelet Agents in Atrial Fibrillation Patients with Concomitant Critical Limb Ischemia: A nationwide cohort study
ConclusionsDOAC was associated with a significantly lower risk of composite net-clinical-benefit outcome than either warfarin or APT in AF patients with concomitant CLI. Further prospective study is necessary to validate the findings in the future.
Source: Canadian Journal of Cardiology - February 19, 2020 Category: Cardiology Source Type: research

Low Persistence of Antithrombotic Agents is Associated with Poor Outcomes after First-ever Acute Ischemic Stroke.
This study investigated the time-trend persistence with antithrombotic agents (AT) and assessed the impact of AT persistence on outcome events and adverse events (AE) within two years after first-ever acute ischemic stroke (IS). METHODS: Using Taiwan's National Health Insurance claims dataset, 7,341 IS subjects hospitalized between 2001 and 2005 with AT prescribed at discharge and survived at least 3 months were followed up for 2 years. Time-trends of AT usage were analyzed. Medication persistence was assessed as the proportion of days covered (PDC) for filled prescription, and categorized into low, intermediate and hi...
Source: Acta Neurologica Taiwanica - February 7, 2020 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research

Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation Who Are Indicated for Standard Dosing
With safety concerns about increasing bleeding, off-label underdosing of non-vitamin K antagonist anticoagulants (NOACs) is common in East Asian patients with atrial fibrillation (AF). We tried to investigate the pattern of NOAC underdosing and associated clinical outcomes in patients with AF who are indicated for standard dosing. Using the Korean National Health Insurance Service database, we evaluated 16568 patients with a new prescription of NOAC who are indicated for standard NOAC dosing and compared 4536 patients with warfarin with respect to thromboembolic events (ischemic stroke or systemic embolization), all-cause ...
Source: The American Journal of Cardiology - February 6, 2020 Category: Cardiology Authors: Min Soo Cho, Ji Eun Yun, Ji Jeong Park, Yun Jung Kim, Jessie Lee, Hyungmin Kim, Duk-Woo Park, Gi-Byoung Nam Source Type: research

Direct Oral Anticoagulants in Atrial Fibrillation Patients with Concomitant Hyperthyroidism.
CONCLUSION: Among NVAF Asian patients with concomitant hyperthyroidism, DOACs may be an effective and safer alternative to warfarin. Thromboprophylaxis with DOACs may be considered for such patients, and it is important to validate this finding in further prospective study. PMID: 32009154 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - February 2, 2020 Category: Endocrinology Authors: Chan YH, Wu LS, See LC, Liu JR, Chang SH, Chao TF, Yeh YH, Kuo CT, Lee HF, Lip GYH Tags: J Clin Endocrinol Metab Source Type: research

Low-Dose Aspirin May Not Reduce Heart Risks for Black Americans, Study Finds
It’s fairly established medical science that people who have had heart attacks can take regular low doses of aspirin to significantly lower their risk of having another heart attack, or other heart problems including stroke. But it is still an open question whether or not people who haven’t had a heart event, but are at higher risk of one (because, for example) they have diabetes, high blood pressure, or elevated cholesterol levels), can also benefit from the over-the-counter painkiller and anti-inflammatory drug. A new study, published in the Journal of the American Heart Association, adds to that debate by ad...
Source: TIME: Health - December 11, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized aspirin Drugs Heart Disease Source Type: news

Comparing the Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin in the Elderly Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.
CONCLUSIONS: Compared to warfarin, NOACs were associated with a significantly lower risk of adverse events, with heterogeneity in treatment effects among different age strata. Overall, the clear safety signal in favor of NOACs over warfarin was evident irrespective of age strata, being most marked in the most elderly. PMID: 31809694 [PubMed - as supplied by publisher]
Source: Chest - December 2, 2019 Category: Respiratory Medicine Authors: Chao TF, Chiang CE, Liao JN, Chen TJ, Lip GYH, Chen SA Tags: Chest Source Type: research

Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea
ConclusionAspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia. Moreover, the benefits of the long-term use of aspirin in reducing the risks of MACCE were demonstrated. However, the decision of using aspirin for primary prevention must be carefully made on an individual basis, while estimating the benefit –risk balance of aspirin.
Source: Drugs and Aging - November 21, 2019 Category: Geriatrics Source Type: research

Prevalence and Associated Stroke Risk of Human Immunodeficiency Virus-Infected Patients With Atrial Fibrillation 　- A Nationwide Cohort Study.
CONCLUSIONS: The risks of ischemic stroke/SE and major bleeding were significantly higher in HIV-infected patients compared with non-HIV-infected patients with AF. Despite this, the actual use of OACs among AF patients with HIV was suboptimal. PMID: 31619594 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 16, 2019 Category: Cardiology Authors: Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Lip GYH, Joung B Tags: Circ J Source Type: research

Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients
Conclusions The presence of comorbidities was linked to NOAC use over vitamin K antagonist, which is different from prescription factor studies in other countries and requires further study.
Source: International Journal of Clinical Pharmacy - September 13, 2019 Category: Drugs & Pharmacology Source Type: research